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Presenilin-mediated endoproteolysis of transmem-
brane proteins plays a key role in physiological
signaling and in the pathogenesis of Alzheimer dis-
ease and some cancers. Numerous inhibitors have
been found via library screens, but their structural
mechanisms remain unknown. We used several
biophysical techniques to investigate the structure
of human presenilin complexes and the effects of
peptidomimetic g-secretase inhibitors. The com-
plexes are bilobed. The head contains nicastrin
ectodomain. The membrane-embedded base has a
central channel and a lateral cleft, which may
represent the initial substrate docking site. Inhibitor
binding induces widespread structural changes,
including rotation of the head and closure of the
lateral cleft. These changes block substrate access
to the catalytic pocket and inhibit the enzyme.
Intriguingly, peptide substrate docking has recip-
rocal effects on the inhibitor binding site. Similar
reciprocal shifts may underlie the mechanisms of
other inhibitors and of the ‘‘lateral gate’’ through
which substrates access to the catalytic site.
INTRODUCTION
Presenilin complexes (also known as g-secretase complexes)
are composed of four core component proteins: presenilin 1(PS1; Sherrington et al., 1995) or presenilin 2 (PS2; Rogaev
et al., 1995); anterior pharynx 1 (aph1; Francis et al., 2002; Goutte
et al., 2002); presenilin enhancer 2 (pen2; Francis et al., 2002);
and nicastrin (Yu et al., 2000) (Figure 1A). A subset of complexes
may also contain one or more regulatory proteins (e.g., trans-
membrane emp24 transport domain-containing protein 10
[Chen et al., 2006] and g-secretase activating protein [He et al.,
2010; St George-Hyslop and Schmitt-Ulms, 2010]). During
maturation and activation of the complex, the presenilin holopro-
teins undergo autocatalytic cleavage to generate N-terminal
fragments (PS1-NTFs) and C-terminal fragments (PS1-CTFs;
Figure 1A; Thinakaran et al., 1996). The mature presenilin com-
plexes then perform the intramembranous endoproteolysis of
several biologically important Type I transmembrane (TM) pro-
teins, including Notch, p75, and the amyloid precursor protein
(APP; Haass and Selkoe, 2007). This cleavage is catalyzed by
two aspartate residues that are thought to be located in a hydro-
philic pocket surrounded by the TM domains of the core com-
plex proteins—one located on TM6 in the PS1-NTF, the other
on TM7 in the PS1-CTF (Wolfe et al., 1999).
The recent crystal structure of MCMJR1 (also known as
Methanoculleus marisnigri presenilin/SSP homolog), a distantly
related Archeal homolog of the human PS1 subunit (19.3%
sequence identity; PDB code 4HYC; Li et al., 2013), confirmed
that the catalytic aspartates are located in a hydrophilic pocket
surrounded by the TM domains of the MCMJR1 protein. How-
ever, many critical questions still remain about the structural
biology of both the Archeon PS1-subunit homolog and the multi-
meric eukaryotic and presenilin complex. For instance, it has
been speculated that substrates may gain access to the active
site of the presenilin aspartyl protease family by a ‘‘lateralStructure 22, 125–135, January 7, 2014 ª2014 The Authors 125
Figure 1. Compound E Binding Induces Conformational Changes in PS1 Complexes that Prevent Detergent-Mediated Dissociation of PS1
Complexes into Hemi-Complexes
(A) Cartoon depicting the hemi-complexes. Substrates have been previously shown to bind to both PS1-NTF and PS1-CTF.
(B) In 0.1% DDM, nicastrin coimmunoprecipitates all complex components: PS1-NTF, PS1-CTF, aph1, and pen2. With increasing detergent concentration,
nicastrin coimmunoprecipitates only aph1 and PS1-CTF.
(C) Incubation of complexes with compound E stabilizes complexes across a range of detergent concentrations.
(D) The compound E-mediated stabilization of the PS1 complexes is dose dependent.
Structure
Structural Mechanisms of PS1 Complex Inhibitorsgate’’ mechanism involving lateral movement of the substrate
TM between the TM domains of the protease. In MCMJR1, it
has been speculated that this might occur via a lateral cleft
between TM6 and TM9 (Li et al., 2013). However, nothing is
known about the mechanics of this putative ‘‘lateral gate.’’ Simi-
larly, although functional screens of chemical libraries have
yielded numerous small molecule inhibitors and modulators
(Wolfe, 2012), the structural mechanisms are unknown for
most of these compounds (Fuwa et al., 2007; Kornilova et al.,
2005; Ohki et al., 2011; Sato et al., 2008; Tian et al., 2002,
2003; Watanabe et al., 2010).
We reasoned that some of these inhibitors, especially highly
potent peptidomimetic inhibitors like compound E, might be
used as tools to explore the functional biology of the presenilin
complex. Such studies could provide insight into the mecha-
nisms by which noncatalytic site inhibitors work. They could
also shed light on both the structural plasticity of the complex
and how long-range interactions within the complex might
modulate its catalytic activity. We chose to use com-
pound E ((S,S)- 2-[2-(3,5-difluorophenyl)-acetylamino]-N-(1-
methyl-2-oxo-5-phenyl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-
yl)-propionamide) for these studies. Compound E is a small
molecule (MW = 490.5 Da) whose backbone structure resembles
a papride bond. This peptidomimetic inhibitor previously has
been shown to bind to a noncatalytic site on PS1-NTF (Fuwa
et al., 2007) and to have very powerful g-secretase inhibitor126 Structure 22, 125–135, January 7, 2014 ª2014 The Authorsactivity (50%maximal inhibitory concentration of 0.3 nM; Seiffert
et al., 2000). The peptidomimetic nature of compound E,
together with its potent and specific inhibitory activity, suggested
that it likely binds to sites on PS1-NTF that are functionally
important in substrate access to the active site of the presenilin
complex.
Here, we report the results of experiments applying several
complementary methods to investigate the structure of the
native human PS1 complex and of the human PS1 complex after
the binding of compound E. We show both directly (by negative-
stain single-particle electron microscopy [EM]) and indirectly (by
biochemical, pharmacological, and intramolecular fluorescent
lifetime imagingmicroscopy—Fo¨rster resonance energy transfer
[FLIM-FRET] methods) that inhibitor binding induces long-range
changes in structure and function of the complex. These
changes include rotation of the nicastrin-containing head
domain, compaction of the membrane-embedded base domain
with closure of the lateral cleft, and functional closure of the initial
substrate docking site. We show that there are also reciprocal
long-range interactions between the initial substrate docking
site and the inhibitor binding site whereby substrate docking
opens the inhibitor binding site. Taken together, these
observations describe the inhibitory mechanism of compound
E. However, our observations also demonstrate that the preseni-
lin complex is structurally dynamic. They show that there are
important reciprocal long-range structural interactions occurring
Figure 2. FLIM-FRET Analysis of Purified, Mature, Catalytically
Active, GFP- and RFP-Tagged PS1 Complexes Confirms that
Compound E Binding Causes Conformational Changes
(A) FRET efficiencies of GFP/RFP-tagged PS1 complexes are improved after
incubation in 10 mMcompound E (DMSO control: 15.46 ± 0.69%mean ± SEM;
10 mM compound E: 18.02 ± 0.95%, n = three independent experiments).
*p% 0.05.
(B) Representative fluorescence decay curves for donor GFP fluorescence
under each experimental condition. G-PS1 and G-PS1-R decay curves and
fluorescence lifetimes were derived from fitting the experimentally observed
photon counts by single exponential decay and double exponential decay
models, respectively. The relationship of the FRET donor-receiver pair on the
two hemi-complexes is displayed in Figure S1A. A western blot demonstrating
complete endoproteolysis and maturation of the GFP/RFP-tagged PS1
complexes is displayed in Figure S1B.
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Structural Mechanisms of PS1 Complex Inhibitorsbetween different sites within the complex and that these struc-
tural interactions have powerful effects on the catalytic activity of
the complex.
RESULTS
Compound E Protects PS1 Complex from
Detergent-Induced Dissociation
We and others (Fraering et al., 2004) have previously shown that
detergents cause a concentration-dependent separation of thepresenilin complex into two hemi-complexes (Figures 1A and
1B). One hemi-complex contains pen2 and PS1-NTF (bearing
one catalytic aspartate on TM6 and one-half of the initial sub-
strate docking site). The other hemi-complex contains nicastrin,
aph1, and PS1-CTF (bearing the other catalytic aspartate on
TM7 and the other half of the initial substrate docking site;
Figures 1A and 1B). However, binding of compound E caused
a dose-dependent resistance to this detergent-induced dissoci-
ation of the two hemi-complexes (Figures 1C and 1D). This
observation suggested that compound E might induce signifi-
cant structural rearrangements in the complex that brings the
component proteins into closer proximity. Such closer proximity
could then promote stronger interactions between the two
hemicomplexes, rendering them resistant to detergent-induced
separation.
Effect of Compound E on Intramolecular FRET
To test this hypothesis, we applied intramolecular FLIM-FRET
methods on PS1 complexes that were doubly tagged with
both GFP at the N terminus and red fluorescent protein (RFP)
at codon 351 (Figure S1A available online). The doubly tagged
PS1 cDNAwas constructed so that, after the physiological endo-
proteolysis of the PS1 holoprotein, the GFP tag at the N terminus
of TM1 would label the <PS1-NTF + pen2> hemi-complex. The
RFP tag at the N terminus of TM7 would label the <PS1-CTF +
aph1 + nicastrin> hemi-complex (Herl et al., 2006; Uemura
et al., 2010). We expressed the GFP-PS1-RFP protein in murine
PS1-PS2 double-knockout fibroblasts and purified the resulting
mature, catalytically active, doubly-tagged PS1 complexes by
wheat germ agglutinin (WGA) chromatography (Figure S1B).
The complexes were then subjected to FLIM-FRET analysis in
the presence or absence of excess compound E. Native com-
plexes exhibited 15.46 ± 0.69% FRET efficiency. In contrast,
complexes with compound E bound had significantly higher
FRET efficiencies (18.02 ± 0.95%, p = 0.0321; Figures 2A and
2B). The higher FRET efficiency in compound E-bound com-
plexes supports the notion that binding of compound E induces
significant structural changes in the complex that result in amore
compact conformation.
Compound E Has Allosteric Effects on the Initial
Substrate Docking Site
The observation that binding of compound E caused significant
conformational changes in the PS1 complex raised the possibil-
ity that these changes might also have long-range (allosteric)
effects on other functional domains of the presenilin complex
(e.g., the initial substrate docking site; Figure 1A). To address
this question, we monitored the docking of a noncleavable sub-
strate in the presence of varying concentrations of compound E
(10 pM–10 mM; Fuwa et al., 2007; Kornilova et al., 2005; Wata-
nabe et al., 2010). Compared with native PS1 complexes,
compound E-bound PS1 complexes showed dose-dependent
reductions in binding of the substrate (Figures 3A and 3B).
Intriguingly, in the reciprocal experiment, preincubation of the
PS1 complex with the noncleavable substrate resulted in
increased binding of labeled compound E (Figure 4). This
enhanced binding of labeled compound E was specific because
it could be blockedwith excess of unlabeled compound E. Taken
together, these experimental results demonstrate a hithertoStructure 22, 125–135, January 7, 2014 ª2014 The Authors 127
Figure 4. Noncleavable Peptidic D-Helical Substrate Mimic and
Compound E Have Reciprocal Allosteric Effects on Each Other’s
Binding to PS1 Complexes
Preincubation of the PS1 complexes with the D-helical substrate mimic
enhanced binding of compound E to the PS1 complex.
Figure 3. Noncleavable Peptidic D-Helical Substrate Mimic and
Compound E Have Reciprocal Allosteric Effects on Each Other’s
Binding to PS1 Complexes and Compound E Inhibits Binding of
the D-Amino-Acid Helical Substrate to the Initial Substrate Docking
Site of PS1 Complexes
(A) A representative blot showing progressive inhibition of D-helical photo-
probe binding to PS1-NTF in the presence of increasing concentrations of
compound E.
(B) Quantitative results of four independent experiments expressed as
percentage of DMSO control. Error bars are SEM.
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the complex. Compound E binding to PS1-NTF ‘‘closes’’ the
initial substrate docking site at the interface of PS1-NTF and
PS1-CTF. Conversely, substrate binding ‘‘opens’’ the compound
E inhibitor binding site.
To investigate the structural basis of these allosteric interac-
tions, we used negative-stain EM to compare the three-
dimensional (3D) structures of native and compound E-bound
complexes.
Human PS1 complexes were captured (in the presence or
absence of compound E) by tagging the N terminus of PS1
with a tandem affinity purification (TAP) tag and expressing the
TAP-tagged PS1 subunit at near-physiological levels in human
embryonic kidney 293 (HEK293) cells. The tagged complexes
were solubilized in digitonin and purified by three-step affinity
chromatography (Figure S2). The resulting complexes were
pure, mono-dispersed, structurally intact, and enzymatically
active (Figures S3A–S3C). The masses of the PS1 protein com-
plex and of the associated detergent molecules were deter-
mined using size exclusion chromatography with multiangle light
scattering (SEC-MALS). The estimated mass of the catalytically
active PS1 complex was 174 kDa, suggesting that the PS1 com-
plex has 1:1:1:1 stoichiometry in solution. The mass distribution
evaluated across the main protein peak was constant, indicating
that there was a single major, highly monodispersed species
(Figure S4). This result is of note because a few prior studies128 Structure 22, 125–135, January 7, 2014 ª2014 The Authorshave suggested that the PS1 complex may exist as a dimer
and because the crystal structure of the Archeon homolog of
the eukaryotic PS1 subunit can be interpreted to suggest that
it exists as a tetramer (Li et al., 2013).
Negative-Stain EM
Native and compound E-bound PS1 complexes were then nega-
tively stained and imaged by EM. The resultant images revealed
individual particles adopting different orientations with charac-
teristic asymmetric, round, oval, or bilobed shapes of 100 A˚
in diameter (Figure 5A; Table 1; Figure S6).
To generate a reliable initial model, we used the random
conical tilt (RCT) method for particles with and without com-
pound E (Benefield et al., 2013; Cheng et al., 2006; Gue´nebaut
et al., 1997; Liu and Wang, 2011; Radermacher et al., 1987;
Stroupe et al., 2006). Corresponding particles from 0 and 45
tilt pairs were picked using e2RCTboxer.py in the Electron
Micrograph Analysis software package (EMAN2; 4,142 native
particle pairs and 990 compound E particle pairs). The 0 tilt
particles were classified using e2refine2d.py in EMAN2. The
3D RCT initial model was reconstructed from 45 particles using
e2rct.py. The initial model created by RCT was initially refined
against the RCT particle data set using the Regularised Likeli-
hood Optimisation software package (RELION), filtered to 30 A˚
using the X-Window-Based Microscopy Image Processing
Package (Scheres et al., 2008; Sorzano et al., 2004), and then
refined against each full data set (11,234 native PS1 particles
and 10,651 compound E particles; Rosenthal and Henderson,
2003) by RELION (Scheres, 2012; Figure S5). The final resolution
was calculated using the ‘‘gold standard’’ Fourier shell correla-
tion (gsFSC; Scheres, 2012) within RELION (0.143 threshold
resolutions for native PS1 = 17.4 A˚; compound E-bound PS1 =
17.4 A˚; Figure 6).
Structure of Native PS1 Complexes
The 3D model constructed for native PS1 complexes (EMDB
accession number: EMD-2477) had generally similar overall
dimensions to those of previously published models (Lazarov
et al., 2006; Ogura et al., 2006; Osenkowski et al., 2009; Renzi
et al., 2011). However, there were several notable differences.
Specifically, the native PS1 complexes had a bilobed conforma-
tion rather than the egg-shaped structures of previous models.
This bilobed shape had a larger base (93 A˚ 3 93 A˚ 3 60 A˚) and
a distinct, smaller head (65 A˚ 3 60 A˚ 3 55 A˚; Figure 7A).
Figure 5. Raw Particles and 3D Model Validation of Human PS1
Complex
(A) CCD image of native PS1 complexes. Representative particle shapes are
highlighted by white boxes; boxes 1–3, bilobed shapes; boxes 4–8, round or
oval shapes; boxes 6–8 show suggestive central cavities. Scale bar, 20 nm.
(B) Classums of native PS1 particles compared with 2D projections of the final
model for native PS1 complexes. The classums and corresponding 2D
projections are highly similar in size, shape, and internal density distribution.
Bilobed, oval, and round shapes are seen that are similar to the raw particle
images. Central cavities in the base domain are apparent in most classum/2D-
projection pairs. Scale bar, 100 A˚. Supplemental information is available,
including a detailed flowchart of the complex purification algorithm (Figure S2),
silver-stained SDS-PAGE gel showing the presence of all complex compo-
nents and blue native PAGE showing their monodispersity and catalytic
activity that can be inhibited by compound E (Figure S3), mass analysis of the
complex using size exclusion chromatography with SEC-MALS (Figure S4),
detailed flowchart of the model-building algorithm (Figure S5), and additional
classum images (Figure S6).
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fact that the N terminus of nicastrin is a relatively large
(105.9 kDa), heavily glycosylated structure that is known to be
located in the lumen/extracellular space. Therefore, we immu-
nolabeled complexes with a monoclonal antibody targeting
residues 168–289 in the N terminus of nicastrin. The size of
the base domains of these immuno-labeled complexes was
not different from that of unlabeled complexes. However, the
size of the head domain was considerably larger than that of
unlabeled complexes (3,949 particles; Figure 8). Labeling com-
plexes with nonspecific anti-mouse IgGs caused no change in
the size of either part of the complex (data not shown). The
absence of a single unique location on the head for the
increased mass contributed by the anti-nicastrin antibody likely
arises from the flexibility of both the antibody and the targeted
single-chain ectodomain of nicastrin. At the current resolution,
this flexibility in 3D space likely caused the added mass of the
antibody to appear as if merged into the mass of the head.
The notion that the head contains the nicastrin ectodomain is
further supported by the fact that the head of the bilobed struc-Table 1. Summary of the Untilted and RCT EM Images, the Number o
General Classes of Particle Class Averages: Round, Oval and Bilobe
Targeted Complexes
Untilted RCT
CCD Image Count Particle Count CCD Image Co
Native PS1 300 11,234 52
CpdE-bound PS1 300 10,651 60
Additional views of 200 class averages built in EMAN2 are displayed in Fture has a volume of 112 nm3. This closely approximates the
calculated volume (128.4 nm3) required to contain the known
mass of the glycosylated nicastrin ectodomain (105.9 kDa). The
other hydrophilic loops in the PS1 complex (residues 1–82 at the
PS1–N-terminus, 9.5 kDa; and residues 265–407 in the TM6-
TM7 loop, 15.7 kDa) are by themselves too small to account
for this structure. Taken together, these observations strongly
suggest that the head of the bilobed complex contains the
ectodomain of nicastri, and is located in the lumen/extracellular
space.
In agreement with a lumenal/extracellular location of the head,
several observations suggest that the base is membrane
embedded. The height of the base (60 A˚) is sufficient to span
the width of most cellular membranes (35–40 A˚; Bondar et al.,
2009; Wang et al., 2007) and would be able to contain the TM
domains of PS1/PS2, pen2, aph1, and nicastrin.
The membrane-embedded base has a cleft on its lateral sur-
face and contains a series of internal low-density volumes (Fig-
ure 7A), which form a central channel that opens onto the
lumenal/extracellular surface (Figure 7A). Depending on the z
axis rotation of the complex, the lower pore of the central
channel may open into the hydrophobic lipid membrane or into
the intracellular space (Figure 7A, right panel). Intriguingly, both
a lateral cleft between TM6 and TM9 (equivalent of PS1-NTF
and PS1-CTF, respectively) and a central channel have been
reported in the crystal structure of the Archaeon homolog of
the PS1 subunit (MCMJR1; Li et al., 2013).
Domain Movement Induced by Compound E Binding
on PS1 Complexes
To investigate the structural basis for the potent g-secretase
inhibitor activity of compound E, we used the same methods
to generate a 3D model of complexes with compound E bound
(EMBD accession number: EMD-2478; Figure 6B). We then
used two procedures to statistically compare the models.
First, we calculated gsFSC curves (Scheres, 2012) for each
model separately. The resultant resolution for both native and
compound E-bound PS1 complexes was 17.4 A˚ (Figure 6), sug-
gesting that the conformational differences observed at this
resolution are likely to be reliable.
Second, we calculated a difference map between the two final
models. The membrane-embedded base domains of the two
models were aligned by ‘‘Fit in Map’’ operation in UCSF Chimera
(Pettersen et al., 2004). The models were highly similar, with a
correlation of 0.93. The aligned map of the native PS1 complex
was then subtracted from that of the compound E-bound PS1
complex, and differences were scored based on thresholding
in units of SD. Differences with SDR 7 were displayed as previ-
ously described (Figure 7C; Wu et al., 2012). Three significantf Particles Investigated, and the Summary Statistics for the Three
d
2D Classums
unt Particle-Pair Count Total Bilobed (%) Oval (%) Round (%)
4,142 200 41 24 35
990 200 21 29 50
igure S6.
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Figure 6. Resolution of the Final Maps as Evaluated by gsFSC
Method
The 0.143 threshold resolution of both the native and compound E-bound PS1
map was 17.4 A˚ resolution.
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Structural Mechanisms of PS1 Complex Inhibitorschanges were evident (Figure 7C). First, there were significant
mass shifts in the head that effectively rotated and tilted it toward
the base. Second, there was significant narrowing or closure of
the lower pore in the base of compound E-bound complexes,
indicating a more compact structure compared with native com-
plexes (Figures 7B and 7C). Finally, the lateral cleft on the surface
of the base appeared to be closed in compound E-bound com-
plexes (Figure 7B).
Comparison with Prior Models
There are several differences between the current and previous
models, which also differed among themselves. The most plau-
sible explanation for these differences is that they arise from the
overexpression strategy (often in heterologous nonhuman cell
systems) that were employed by all of these previous studies
(Lazarov et al., 2006; Osenkowski et al., 2009; Renzi et al.,
2011). Such overexpression systems are well known to cause
distortions in component stoichiometry of PS1 complexes and
incomplete glycosylation of nicastrin (Kimberly et al., 2003).
The inclusion of even a small subset of complexes with an
abnormal stoichiometry or with incomplete glycosylation of
nicastrin would introduce hidden heterogeneity into the sample
and cause blurring of the details of the structure.
To circumvent this problem, we deliberately incorporated
three features into our purification strategy. First, we used
human cells that expressed endogenous, physiologically pro-
cessed human nicastrin, aph1, and pen2. Second, the only
exogenous protein (human PS1) was expressed at near-physio-
logical levels. Finally, we used a multi-step affinity purification
protocol designed to eliminate complexes that did not contain
both the tagged PS1 and mature nicastrin. We also exploited
the higher contrast of negative-stain EM methods which, for
small membrane-bound particles with potentially attached lipid,
may provide advantages over cryo-EM methods.
Validation
Single-particle EM of particles of <400 kDa with low symmetry
must be interpreted with great care to ensure that 3D models
represent the true shapes of the protein particles (see review,
Frank, 2006, 2009; Henderson et al., 2012). We present our
data with this caveat in mind. However, three features of our130 Structure 22, 125–135, January 7, 2014 ª2014 The Authorsanalysis support the notion that the models presented here are
probably correct. First, the same bilobed 3D structure was
obtained when themodel-building process employed an angular
reconstruction approach with initial seeding using either bilobed
or egg shapes. Second, the same bilobed shape was obtained
using an independent data set of particles (n = 3,074 particles).
Finally, orientations of the final 3D models built using the RCT-
based approach (and two-dimensional [2D] projections of that
3Dmodel) could be found that closely matched both representa-
tive raw images (Figure 5A) and reference-free class averages
(‘‘classums’’) built independently in EMAN2 (Figure 5B).
DISCUSSION
The experimental results reported here provide four important
observations about the structural and functional biology of the
presenilin complex.
The first significant outcome of our work is that, by taking
advantage of the higher contrast of negative-stain EM methods
and by employing an expression/purification protocol that
avoids distorting complex stoichiometry, we are able to provide
details about the structure of the presenilin complex. Although
generally similar in dimensions to previous models (Lazarov
et al., 2006; Osenkowski et al., 2009; Renzi et al., 2011), the 3D
model presented here has a bilobed shape with distinct head
and body domains. The head contains the ectodomain of
nicastrin.
Second, in addition to clarifying the general topology of the
complex, our work provides further architectural details that
were not agreed upon in prior models. In particular, the mem-
brane-embedded base may contain a lateral cleft and a central
channel. Similar elements have been observed in the 3.3-A˚ crys-
tal structure of the Archaeon PS1 subunit homolog. In the
Archaeon PS1-subunit homolog, the easily discernible central
channel has been interpreted to represent a hydrophobic
channel that is distinct from an adjacent shallow solvent-acces-
sible hydrophilic catalytic cavity. However, when the MCMJR1
structure is rendered at 17 A˚, the shallow catalytic cavity is not
well resolved. Consequently, we are therefore unable to map
the corresponding feature on our models.
The distinct cleft between TM6 of the Archeon PS1 subunit
(which would be contained in the eukaryotic PS1-NTF hemi-
complexes) and TM9 (which would be contained in the
eukaryotic PS1-CTF hemi-complexes) has been proposed as a
potential initial substrate docking site that might then operate
as part of a ‘‘lateral gate’’ mechanism to provide substrate
access to the active site (Li et al., 2013). Additional studies will
be required to determine whether the lateral cleft observed
here in the base of human PS1 complexes also represents the
initial substrate docking site. Our pharmacological data provide
circumstantial evidence that it may be. Thus, binding of com-
pound E to the complex causes the closure of both the function-
ally defined initial substrate docking site and the biophysically
defined lateral cleft.
The apparent rotation and tilting movement of the nicastrin-
containing head in the presence of compound E is of interest.
Although controversial, the ectodomain of nicastrin has been
proposed to bind the exposed N-terminal stub of substrate pro-
teins after their cleavage by a ‘‘sheddase’’ such as beta-site APP
Figure 7. Top-Down Vertical, Lateral, and Cross-Sectional Views of 3D Reconstructions of PS1 Complexes Reveal that Both Native PS1
Complexes and Compound E-Bound Complexes Have an Irregular Bilobed Shape
(A) The native PS1 complex contains a head domain and a base domain. The base domain has a lateral cleft and central cavity/channel, which appears to open
onto the upper/extracellular surface and also onto the lower surface via a smaller pore. The shaded lipid bilayer represents the boundaries of a putative
membrane.
(B) 3D reconstructions of compound E-bound PS1 complexes reveal a similar structure, with the rotation and tilting of the head. Density shifts on the external
surface of the base result in closure of the lateral cleft and of the lower pore of central channel.
(C) Corresponding vertical and lateral views of the differencemap, whichwas calculated using the UCSFChimera package. Bluemesh is the native PS1 complex,
and the pink mesh is compound E-bound PS1. Positive density is represented in green. Negative density is displayed in red. A detailed flowchart of the model-
building algorithm is available in Figure S5. A rotating animated video of the native complex built in chimera (Movie S1) and an animated video comparing the
native and compound E complexes (Movie S2) are available in online supplemental data files.
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Structural Mechanisms of PS1 Complex Inhibitorscleaving enzyme (Shah et al., 2005). The observed flexibility of
the nicastrin-containing head could facilitate such interactions
by bringing the N-terminal ectodomain of nicastrin into closer
physical proximity with the N-terminal membrane-bound stub
of the substrate.
A third important outcome of the experiments reported here is
that they reveal how some non-transition-state g-secretase
inhibitors work. We show that binding of compound E to its bind-
ing site on PS1-NTF induces significant allosteric conformational
changes in the complex, including closure of the initial substrate
docking site. These allosteric effects presumably interfere with
the binding and translocation of substrates to the active site.
Intriguingly, there is reciprocal crosstalk from the initial substrate
docking site to the compound E binding site. Substrate docking
increases compound E binding.
It is likely that other small-molecule inhibitors, including the
clinically promising class of g-secretase modulator (GSM) com-pounds, may work through similar allosteric mechanisms.
Indeed, some of the GSMs bind to PS1-NTF (Ohki et al., 2011)
and require prior substrate docking for their inhibitor activity
(Uemura et al., 2010). Furthermore, these interactions between
inhibitor binding sites and initial substrate docking sites are
also sometimes substrate specific (e.g., APP but not Notch;
Sagi et al., 2011). Additional experiments of the type reported
here may help understand the allosteric mechanisms of GSMs
at a higher resolution.
Finally, our work suggests that the eukaryotic presenilin com-
plex is likely to be structurally highly dynamic. This structural
flexibility might underlie other functionally important long-range
interactions within the complex. For example, the operation of
the putative ‘‘lateral gate,’’ which governs access of substrate
peptides to the catalytic pocket, will likely require reciprocal
interactions between the initial substrate binding site and other
sites within the complex. These interactions will be required toStructure 22, 125–135, January 7, 2014 ª2014 The Authors 131
Figure 8. Antibodies to the Ectodomain of Nicastrin Label the Head
Domain, Indicating that the Head Domain Is Lumenal/Extracellular
Representative class average images of native and anti-nicastrin anti-
body-labeled PS1 complexes reveal that anti-nicastrin antibody-labeled
complexes have an increased density of the head domain. The box width is
261.12 A˚.
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Structural Mechanisms of PS1 Complex Inhibitors‘‘open’’ the gate upon substrate binding and then ‘‘close’’ the
gate during peptide translocation to active-site pocket. Our
observation of just such reciprocal crosstalk between the initial
substrate docking site and the compound E binding site is highly
relevant in this regard. Indeed, it is conceivable that the same (or
very similar) reciprocal interactions described here between the
initial substrate binding site and the compound E binding site are
part of this putative ‘‘lateral gate’’ mechanism. Similar long-
range dynamic structural effectsmight also explain how synaptic
activity and mutations at diverse locations in the PS1 peptide all
affect the relative rates of production of Ab40 and Ab42 species
(Dolev et al., 2013).
EXPERIMENTAL PROCEDURES
Lentiviral Expression of TAP-Tagged Human PS1 in HEK293 Cells
Human PS1 cDNA was tagged at the 50 end with a TAP tag cassette (Bu¨rck-
stu¨mmer et al., 2006) composed of Protein G and streptavidin binding peptide
tags separated by a tobacco etch virus protease cleavage site. The tagged
cDNAwas incorporated into a lentiviral vector, transfected into HEK293T cells,
and then expressed at near-physiological levels using the WAVE bioreactor
system (GE Healthcare).
Protein Purification
HEK293F cells were harvested at a density of 3 million cells/ml, homogenized
in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 5 mM MgCl2, 5 mM
CaCl2 at 4
C. Cells were lysed in the same buffer containing protease inhibitor
cocktail (Roche), 1% (w/v) digitonin (Calbiochem) for 1 hr, and centrifuged at
100,0003 g for 1.5 hr. PS1 complexes were captured on a rabbit IgG-agarose
column (Sigma-Aldrich), washed with 100 column volumes of buffer contain-
ing 0.04% (w/v) digitonin, cleaved with AcTEV protease (Invitrogen), and
eluted with buffer containing 0.04% digitonin. The eluate was purified by
Strep-Tactin chromatography (IBA GmbH); eluted in 0.04% digitonin, 5 mM
desthiobiotin (Sigma-Aldrich); concentrated on WGA agarose beads (Vector
Laboratories); and eluted with buffer containing 0.04% digitonin and 0.5 M
N-acetyl-D-glucosamine. Protein purity was assessed using NuPAGE Bis-Tris
gels (Invitrogen) with silver staining (Pierce). Monodispersity was determined
by western blotting of NativePAGE Novex Bis-Tris Gels (Invitrogen) using
anti-nicastrin (Sigma N1660) and anti-PS1-NTF (Abcam ab10281) antibodies
and compared with NativeMark Unstained Protein Standard (Invitrogen
LC0725).
Compound E-bound complexes were purified as above in 0.5–1.0 mM
compound E during all steps.
g-Secretase Activity Assay
g-Secretase activity of the PS1 complex was measured by ELISA (Human
Ab40 ELISA Kit; Invitrogen) as described previously (Yu et al., 2000).132 Structure 22, 125–135, January 7, 2014 ª2014 The AuthorsEM
Carbon-coated 400-mesh copper grids were glow discharged in air at 600–
700 V for 30–60 s on an Edward S150B sputter coater. Tobacco mosaic virus
was mixed with the sample at 0.03 mg/ml. A total of 1.5–3.0 ml of the protein
mixture (20 ml/ml) was loaded onto the grid; incubated for 1–2 min; washed
five times in 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 2 mM EDTA, 5 mM
MgCl2, 5 mMCaCl2; and blotted on Whatman No. 1 paper. Grids were stained
by floating on drops of 1% uranyl acetate for 2–10 s, and the excess of staining
reagent was blotted away. The grids were imaged with an FEI Tecnai 12
electron microscope operated at 120 kV. Images were recorded at 67,0003
nominal magnification on a 2K 3 2K TVIPS 224 charge-coupled device
(CCD) camera, resulting in final sampling of 2.04 A˚/pixel after correction for
the post column magnification.
3D Reconstruction of Native and Compound E-Bound Complexes
Particles were picked by e2boxer.py (EMAN2) interactively using a square box
size of 128 pixels. A total of 11,234 native PS1 particles from 287 CCD images
and 9,860 compound E-bound PS1 complex particles from 300 CCD images
were picked.
The RCT reconstruction procedure was used for building the reference
model. Tilt-pair images for native and compound E-bound PS1 particles
were collected as described above, using a 45 tilt angle. A total of 4,142 pairs
of native PS1 particles and 990 pairs of compound E-bound particles were
picked by EMAN2 (e2RCTboxer.py). The 3D reconstruction procedure is as
described in Results. Simultaneously, we also used the EMAN2 protocol for
generating random initial models (e2initialmodel.py) based on the common-
lines method. The 2D reference-free alignment and classification of particle
projections were performed following EMAN2 routines (e2refine2d.py).
Particles in each data set (11,234 native PS1 particles and 10,651 compound
E particles) were classified to 200 classes using a multivariate-statistical-
analysis-based, reference-free classification algorithm. Models calculated
using different methods agreed well with each other.
The final 3D model building was as described in Results. Each initial map
was refinedwith the full data set of untilted images (11,234 native PS1 particles
and 9,860 compound E particles) by RELION (Scheres, 2012). The resultant
resolution, as assessed with the gsFSC method (Scheres, 2012), was 17.4 A˚
for both native PS1 and compound E-bound PS1 complexes.
The density was then displayed using the UCSF Chimera package (Pet-
tersen et al., 2004), representing a mass of 200 kDa with included volume of
2.453 105 A˚3, assuming a protein density of 1.37 g/cm3. This mass is consis-
tent with both the calculated mass of each component protein (215 kDa of PS1
protein complex plus glycosylation) and the protein mass (174 kDa) deter-
mined by multi-angle light scattering (Figure 8).
EM-derived density maps have been deposited into the EMDB with
EMBD accession numbers: EMD-2477 (native PS1 complex) and EMD-2478
(compound E-bound PS1 complex).
Immunolabeling
PS1 complexes were immunolabeled by mixing with anti-nicastrin antibody
(0.1 mM; BD Transduction Laboratories 612290) at a 1:1 molar ratio on ice
for 2 hr; applied to 200 ml Strep-Tactin MacroPrep resin pre-equilibrated
with buffer containing 0.04% digitonin; mixed for 1 hr at room temperature;
briefly centrifuged; and then washed twice in 100 ml buffer containing 0.04%
digitonin. Anti-nicastrin antibody-labeled complexes were eluted with 5 mM
desthiobiotin, checked by western blotting, immobilized on carbon-coated,
glow-discharged copper grids, and imaged.
Detergent-Induced PS1 Complex Dissociation
Microsomal membranes from native HEK293 cells were pelleted and homog-
enized in 25 mM HEPES pH 7.4, 1 mM EDTA, 0.25 M sucrose, complete
protease inhibitor cocktail (Roche); centrifuged at 3,000 3 g for 10 min; and
the supernatant was then centrifuged at 100,0003 g for 1 hr. The microsomal
membrane was preincubated with 1% DMSO or 10 pM–100 nM of compound
E overnight. Equal amounts of microsomal membranes were solubilized in
25mMHEPES pH 7.4, 150mMNaCl, 2mMEDTA, complete protease inhibitor
cocktail with 0.1% (w/v) dodelcyl maltoside (DDM; Affimetrix) for 1 hr. The
homogenates were centrifuged at 100,0003 g for 30 min, and the supernatant
was collected. DDMwas added to final DDM concentrations of 0.5%, 1%, and
Structure
Structural Mechanisms of PS1 Complex Inhibitors1.5%. Membrane lysates were incubated overnight at 4C with anti-nicastrin
antibody and Protein G-Sepharose (GE Healthcare). After washing, the
captured proteins were eluted with 13 sample buffer (lithium dodecyl sulfate
[LDS]; Invitrogen). Samples were resolved on 12% Bis-Tris NuPAGE gels
(Invitrogen), transferred onto polyvinylidene fluoride (PVDF) membranes, and
probed with anti-nicastrin, PS1-NTF, aph1 (Covance PRB-550P), PS1-CTF
(Chemicon MAB5232), and pen2 (Sigma P5622).
FLIM-FRET
Double-tagged PS1 complexes were generated by placing GFP at the N
terminus of human PS1 and by placing RFP carboxy-terminal to the endopro-
teolysis site in the TM6-TM7 cytoplasmic loop domain (Herl et al., 2006). PS1/2
double-knockout mouse embryonic fibroblasts stably expressing GFP-PS1
(as a control) or GFP-PS1-RFP were solubilized in 1% (w/v) digitonin Tris
buffer, enriched with WGA resin, and eluted with 0.5 M N-acetyl-D-glucos-
amine in 0.1% digitonin (w/v) Tris buffer. Protein samples were preincubated
overnight with DMSO or 10 mM compound E. The samples were loaded into
0.36-mm-thick borosilicate square capillaries (VitroCom) and sealed with
powdered acrylic resin (Lang Dental Manufacturing) with fast curing glue. A
SpectraPhysics MaiTai laser (Newport) at 850 nm was used to achieve
two-photon excitation of the GFP donor fluorophore. The samples were
imaged at 403 with a 515/30 emission filter. Fluorescence lifetime data were
acquired using the Becker and Hickl system. The GFP fluorescence lifetimes
were fitted to two exponential decay curves and mapped by pseudocolor on
a pixel-by-pixel basis over the entire image. Fluorescence lifetimes were
converted into FRET efficiency, expressed as follows: FRET efficiency =
(tcontrol  tFRET)/tcontrol 3 100, where tcontrol is the GFP lifetime in the GFP-
PS1 construct and tFRET is the GFP lifetime in the GFP-PS1-RFP constructs.
Two-tailed unpaired t tests were performed (PRISM version 5; GraphPad),
where a p value < 0.05 was considered significant.
Photo Crosslinking of Noncleavable Substrate
A total of 400–500 mg of microsomal membrane proteins was solubilized in
HEPES buffer (25 mM HEPES pH 7.4, 150 mM NaCl, 2 mM EDTA) containing
1% 3-([3-cholamidopropyl]dimethylammonio)-2-hydroxy-1-propanesulfonate
and incubated with 10 pM–10 mM compound E. After preclearing with
streptavidin-agarose resin (Pierce), membrane lysates were incubated with
100 nM of biotinylated, UV crosslinkable D-helical substrate mimic for 1 hr
(Kornilova et al., 2005; Watanabe et al., 2010) and then exposed to 365 nm
UV (B100A UV lamp; UV Products) at 7 cm for 40–45 min on ice. Lysates
were denatured with 1% nonyl phenoxypolyethoxylethanol, 0.5% sodium
deoxycholate, and 0.1% SDS, incubated in streptavidin-agarose resin
overnight, and washed. Biotinylated proteins were eluted with 13 LDS sample
buffer, resolved on 12% Bis-Tris PAGE gels, transferred onto PVDF mem-
branes, and then probed with anti-PS1-NTF antibodies. Densitometric
analysis used ImageJ (version 1.45; National Institutes of Health). Two-tailed
unpaired t tests (PRISM, version 5; GraphPad) were used. A p value < 0.05
was considered significant. The reciprocal experiment, in which PS1 was
photo-crosslinked with biotinylated, UV-crosslinkable compound E, was
carried out as previously described (Fuwa et al., 2007).
Mass Analysis by SEC-MALS
SEC-MALS was used to determine the mass of the PS1 complex, which was
resolved on a Superdex S-200 10/300 analytical SEC column (GE Healthcare)
in Tris buffer with 0.1% (w/v) digitonin and detected by UV at 280 nm (Agilent
1200 MWD), light scattering (Wyatt Heleos II), and refractive index (Wyatt
Optilab rEX). Themasses of the PS1 protein complex and digitonin were deter-
mined using the dual detection method as implemented in Wyatt’s ASTRA
analysis software as conjugate analysis. The protein refractive index increment
used was 0.186 ml g1, and the extinction coefficient for UV detection at
280 nm was 1470 ml g-1 cm-1 for the PS1 complex. The digitonin refractive
index increment was 0.153 ml/g (Burgard, 2009), and the digitonin extinction
coefficient for UV detection at 280 nm used was 15 ml/g/cm. The UV value
was determined from control measurements of digitonin, injected from a
concentrate stock solution in which refractive index (RI) analysis indicated a
micelle mass of 115 kDa, in agreement with literature values (Burgard,
2009). The UV signal during these measurements was then used to analyze
the micelle mass and the UV extinction coefficient was adjusted until a massconsistent with the value determined by RI was obtained. The interdetector
delay volumes and associated band broadening constants, as well as the
detector intensity normalization constants for the Heleos and the UV intensity
calibration, were determined prior to each set of measurements using known
protein standards (IgG and BSA).
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